[HTML][HTML] Semaglutide and cardiovascular outcomes in obesity without diabetes

AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
… 8 and diabetes 9,10 is standard evidence-based practice, the concept of treating obesity to
reduce the risk of cardiovascular … for overweight or obesity improve cardiovascular outcomes. …

[HTML][HTML] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in …

I Lingvay, J Deanfield, SE Kahn, PE Weeke… - Diabetes …, 2024 - diabetesjournals.org
… whether the cardiovascular outcomes of semaglutide versus … of semaglutide versus placebo
on cardiovascular outcomes … whether the cardiovascular benefits of semaglutide are only …

[HTML][HTML] Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

DH Ryan, I Lingvay, HM Colhoun, J Deanfield… - American heart …, 2020 - Elsevier
outcome and demonstrates reduced CVD events in persons with obesity and prior CVD
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
… The primary composite outcome was the first occurrence of cardiovascular death, nonfatal
… We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. …

Cardiovascular outcome trials in obesity: a review

JPH Wilding, S Jacob - Obesity reviews, 2021 - Wiley Online Library
… liraglutide and semaglutide improved CV and renal outcomes with no apparent
differences across BMI groups. However, subgroup analysis of the EMPA-REG OUTCOME (empagliflozin…

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

I Lingvay, K Brown‐Frandsen, HM Colhoun… - …, 2023 - Wiley Online Library
… administered dose of 2.4 mg semaglutide on CV outcomes compared with placebo in people
without diabetes but who were living with overweight or obesity and who suffered from a …

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes

M Husain, AL Birkenfeld, M Donsmark… - … England Journal of …, 2019 - Mass Medical Soc
… We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven,
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular

[PDF][PDF] SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes

G Gajos - Cardiology Journal, 2024 - journals.viamedica.pl
… — and to lower the risk of cardiovascular disease in patients with diabetes [1, 3]. Therefore,
I … SELECT study (Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes) …

[HTML][HTML] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

DH Ryan, I Lingvay, J Deanfield, SE Kahn, E Barros… - Nature medicine, 2024 - nature.com
… In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in …
established CVD and overweight or obesity but without diabetes. In SELECT, semaglutide was …

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review

Y Deng, A Park, L Zhu, W Xie… - Therapeutic advances in …, 2022 - journals.sagepub.com
… with diabetes. While few reviews focused on obese/overweight individuals without diabetes,
we aimed to perform a systematic review of semaglutide and liraglutide in randomized …